DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Amikacin (Amikacin Sulfate) - Published Studies

 
 



Amikacin Related Published Studies

Well-designed clinical trials related to Amikacin

Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. [2011.08]

Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [2011.07.01]

Population pharmacokinetics of amikacin in a Korean clinical population. [2011.06]

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. [2011.05]

The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. [2011.02]

Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]

Impact of infusion method on amikacin serum levels in humans. [2010.08]

Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. [2010.04]

Effect of topical application of 1% diclofenac sodium liposomal cream on inflammation in healthy horses undergoing intravenous regional limb perfusion with amikacin sulfate. [2009.11]

Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. [2009.09]

Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. [2009.04]

A comparative study to assess the effect of amikacin sulfate bladder wash on catheter-associated urinary tract infection in neurosurgical patients. [2009.01]

Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. [2008.05]

[Dynamic changes of blister fluid amikacin concentration after its early-stage administration in severely burned patients] [2007.10]

Efficacy and renal toxicity of one daily dose of amikacin versus conventional dosage regime. [2007.02]

Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. [2005.11.21]

Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II. [2005.11]

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. [2005.06]

Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. [2005.01]

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. [2004.07.15]

Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. [2004]

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. [2003.12]

Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. [2003.07]

Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial. [2003.06]

Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma. [2003.04]

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. [2002.07]

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients. [2002.01]

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. [2001.10.15]

Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies. [2001.10]

Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. [2001.09]

Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. [2001.06]

The early bactericidal activity of amikacin in pulmonary tuberculosis. [2001.06]

Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. [2001.04]

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. [2001.03]

Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. [2001.02]

Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. [2001]

Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. [2000.12]

Isepamicin versus amikacin for the treatment of acute pyelonephritis in children. [2000.02]

Pharmacokinetic changes of theophylline and amikacin through the menstrual cycle in healthy women. [1999.12]

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. [1999.09]

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. [1999.07]

Once versus twice daily amikacin in neonates: prospective study on toxicity. [1999.06]

[Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study] [1999.02]

A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. [1998.12.24]

[Comparative study of meropenem and amikacin/metronidazole combination in the treatment of severe abdominal surgical infections] [1998.11.08]

Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections. [1998.10]

Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. [1998.09]

Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. [1998.07]

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. [1998.02]

Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. [1998.02]

[Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections] [1998]

Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. [1997.11]

A comparison of two amikacin dosing regimens in paediatric surgical patients. [1997.09]

Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. [1997.06]

Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. [1997.04]

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. [1997.01]

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. [1996.05]

[Amikacin in single daily doses in children with fever] [1996.01]

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. [1996]

Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. [1995.10]

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. [1995.07]

Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. [1995.07]

A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. [1995.06]

Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. [1995.06]

Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. [1995.06]

The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. [1995.06]

Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms. [1995.06]

The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. [1995.06]

Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. [1995.06]

[Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients] [1995.03]

[Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'etude des Aplasies Febriles] [1995.02.25]

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. [1995.02]

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. [1994.10]

[Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections] [1994.09]

Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3 and 5-day-old foals. [1994.09]

Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. [1994.07]

Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. [1994.07]

Urinary phospholipids excretion in neonates treated with amikacin. [1994]

Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. [1993.06]

Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. [1993.03]

Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. [1993.03]

Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. [1993.01]

Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. [1993]

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. [1992.12]

[Study of the ototoxicity of amikacin and netilmicin using provoked acoustic oto-emissions and high-frequency audiometry] [1992.12]

[Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin] [1992.10]

Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin. [1992.09]

[Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study] [1992.08]

Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. [1992.08]

Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. [1992.08]

A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. [1992.02]

Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation. [1992]

A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections. [1991.12]

A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. [1991.11]

Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. [1991.10]

Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. [1991.05]

Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. [1991.05]

The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. [1991.05]

Pharmacokinetic evaluation of single daily dose amikacin. [1991.05]

Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. [1991.05]

Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group. [1991.05]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012